(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...
Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform ...
The Times of Israel on MSN4d
Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trialsAs part of the collaboration, drugmaker will use Immunai's AI model of the immune system and machine learning for clinical ...
Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
Sept 26 (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more ...
(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm’s AI model of the immune system to make certain cancer drug trials more efficient, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback